Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) shares traded down 1.1% during mid-day trading on Thursday . The company traded as low as $1.92 and last traded at $1.94. 1,000 shares were traded during trading, a decline of 94% from the average session volume of 15,587 shares. The stock had previously closed at $1.96.
Medexus Pharmaceuticals Stock Down 1.1 %
The firm has a 50 day simple moving average of $1.84 and a 200 day simple moving average of $1.50.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
- Five stocks we like better than Medexus Pharmaceuticals
- How to Start Investing in Real Estate
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Dividend Capture Strategy: What You Need to Know
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Ride Out The Recession With These Dividend Kings
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
